UMB Bank n.a. Buys 4,153 Shares of AstraZeneca PLC (NASDAQ:AZN)

UMB Bank n.a. lifted its position in AstraZeneca PLC (NASDAQ:AZN) by 34.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 16,041 shares of the company’s stock after purchasing an additional 4,153 shares during the period. UMB Bank n.a.’s holdings in AstraZeneca were worth $1,051,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of AZN. Diversify Wealth Management LLC grew its stake in AstraZeneca by 3.6% in the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after acquiring an additional 153 shares during the period. Clarius Group LLC grew its position in shares of AstraZeneca by 3.3% in the 4th quarter. Clarius Group LLC now owns 10,542 shares of the company’s stock valued at $691,000 after purchasing an additional 334 shares during the period. Oak Ridge Investments LLC increased its stake in AstraZeneca by 5.4% during the 4th quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company’s stock worth $9,433,000 after purchasing an additional 7,341 shares in the last quarter. Aaron Wealth Advisors LLC raised its holdings in AstraZeneca by 8.3% during the 4th quarter. Aaron Wealth Advisors LLC now owns 18,842 shares of the company’s stock worth $1,235,000 after buying an additional 1,440 shares during the period. Finally, Veery Capital LLC lifted its stake in AstraZeneca by 4.7% in the fourth quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after buying an additional 157 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on AZN shares. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Up 2.0 %

Shares of NASDAQ:AZN opened at $67.96 on Wednesday. The stock has a market capitalization of $210.75 billion, a PE ratio of 32.52, a price-to-earnings-growth ratio of 1.04 and a beta of 0.46. The company’s 50-day moving average price is $66.14 and its two-hundred day moving average price is $74.39. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.87 earnings per share. On average, equities analysts forecast that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.